Gail Farfel
Directeur/Membre du Conseil chez DURECT CORPORATION
Fortune : 118 764 $ au 31/05/2024
Postes actifs de Gail Farfel
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| DURECT CORPORATION | Directeur/Membre du Conseil | 25/04/2019 | - |
| Independent Dir/Board Member | 25/04/2019 | - | |
| AVROBIO, INC. | Directeur/Membre du Conseil | 21/10/2020 | - |
PrintedArt
 PrintedArt Other Consumer ServicesConsumer Services PrintedArt provides photography and printing services. | Directeur/Membre du Conseil | - | - |
| American Society For Experimental Neurotherapeutics | Directeur/Membre du Conseil | - | - |
FAAH Pharma, Inc.
 FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Directeur/Membre du Conseil | 07/08/2014 | - |
Historique de carrière de Gail Farfel
Anciens postes connus de Gail Farfel
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| PROMIS NEUROSCIENCES, INC. | Directeur/Membre du Conseil | 29/06/2023 | 30/12/2023 |
| Directeur Général | 19/09/2022 | 30/12/2023 | |
| President | 19/09/2022 | 30/12/2023 | |
| ZOGENIX, INC. | Corporate Officer/Principal | 01/06/2015 | 01/09/2022 |
| MARINUS PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/12/2012 | 01/06/2015 |
| Conseiller Juridique Général | 01/12/2012 | 01/06/2015 | |
| G Meredith Consulting LLC | President | 01/05/2008 | 01/12/2012 |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Formation de Gail Farfel
| The University of Chicago | Doctorate Degree |
| University of Virginia | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 13 |
| Canada | 3 |
| Royaume-Uni | 2 |
Opérationnelle
| Director/Board Member | 7 |
| Corporate Officer/Principal | 4 |
| President | 2 |
Sectorielle
| Health Technology | 11 |
| Consumer Services | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| MARINUS PHARMACEUTICALS, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| DURECT CORPORATION | Health Technology |
| AVROBIO, INC. | Health Technology |
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Pfizer Pharmaceuticals, Inc.
 Pfizer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Pfizer Pharmaceuticals, Inc. is an American company that manufactures pharmaceutical products. | Health Technology |
PrintedArt
PrintedArt Other Consumer ServicesConsumer Services PrintedArt provides photography and printing services. | Consumer Services |
| G Meredith Consulting LLC | |
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
Zogenix International Ltd.
 Zogenix International Ltd. Pharmaceuticals: MajorHealth Technology Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom. | Health Technology |
| American Society For Experimental Neurotherapeutics | |
FAAH Pharma, Inc.
FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Health Technology |
- Bourse
- Insiders
- Gail Farfel
- Expérience
